HC Wainwright Reaffirms Buy Rating for Blueprint Medicines (NASDAQ:BPMC)
HC Wainwright reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $85.00 price target on the biotechnology company’s stock. A number of other equities research analysts have also issued reports on BPMC. Barclays upped their target price on […]
More Stories
South Carolinians Go to Polls for Key Republican Senate Primary
By Joseph Lord CHARLESTON, S.C.—South Carolina voters will head to the polls today to make their pick in a runoff...
Iran Vows to Retaliate After US Rolls Out ‘Economic D-Day’ Sanctions
By Owen Evans Iran has promised to retaliate against the United States after Washington rolled out an “economic D-Day” sanctions...
ICE Arrests More Than 1,300 Illegal Immigrants in Virginia, Maryland in 2-Week Operation
By Aldra Fredly Immigration and Customs Enforcement (ICE) arrested more than 1,300 illegal immigrants during a two-week operation in Virginia...
Bessent Warns China, Others Not to Test US Resolve on Iran Sanctions
By Andrew Moran and Emel Akan Bessent, at an Aug. 24 news conference, unveiled the contours of the administration’s sweeping...
Gold Prices Surge to Highest Level in Over 3 Months
By Naveen Athrappully Gold prices are trading at their highest level in more than three months on Monday, amid continued...
Treasury, IRS Propose Rules on Trump Account Investments
By Naveen Athrappully The Department of the Treasury and the IRS have issued proposed regulations clarifying which investments may be...